HK1216903A1 - 抗體-尿素酶偶聯物在診斷和治療中的應用 - Google Patents

抗體-尿素酶偶聯物在診斷和治療中的應用

Info

Publication number
HK1216903A1
HK1216903A1 HK16104650.5A HK16104650A HK1216903A1 HK 1216903 A1 HK1216903 A1 HK 1216903A1 HK 16104650 A HK16104650 A HK 16104650A HK 1216903 A1 HK1216903 A1 HK 1216903A1
Authority
HK
Hong Kong
Prior art keywords
diagnostic
antibody
therapeutic purposes
urease conjugates
urease
Prior art date
Application number
HK16104650.5A
Other languages
English (en)
Inventor
巢立文
Original Assignee
Helix Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helix Biopharma Corp filed Critical Helix Biopharma Corp
Publication of HK1216903A1 publication Critical patent/HK1216903A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01005—Urease (3.5.1.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16104650.5A 2013-04-08 2016-04-22 抗體-尿素酶偶聯物在診斷和治療中的應用 HK1216903A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361809842P 2013-04-08 2013-04-08
PCT/CA2014/050334 WO2014165985A1 (en) 2013-04-08 2014-04-03 Use of antibody-urease conjugates for diagnostic and therapeutic purposes

Publications (1)

Publication Number Publication Date
HK1216903A1 true HK1216903A1 (zh) 2016-12-09

Family

ID=51688787

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16104650.5A HK1216903A1 (zh) 2013-04-08 2016-04-22 抗體-尿素酶偶聯物在診斷和治療中的應用

Country Status (8)

Country Link
US (1) US10316311B2 (zh)
EP (1) EP2984170A4 (zh)
JP (1) JP2016524459A (zh)
CN (2) CN105247047A (zh)
AU (1) AU2014252666B2 (zh)
CA (1) CA2908475C (zh)
HK (1) HK1216903A1 (zh)
WO (1) WO2014165985A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107206103A (zh) * 2015-01-23 2017-09-26 赫利克斯生物药品公司 用于治疗目的的抗体‑脲酶缀合物
WO2018053639A1 (en) 2016-09-24 2018-03-29 Helix Biopharma Corp. Restoring function of tumour acidified t cells
EP3580242A4 (en) * 2017-01-05 2021-01-13 Helix Biopharma Corp. ANTI-VEGFR-2-UREASE CONJUGATES

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218539A (en) * 1978-03-24 1980-08-19 Weltman Joel K Enzyme conjugates and method of preparation and use
US4360592A (en) * 1979-11-13 1982-11-23 Weltman Joel K Process for the detection of antibodies
US4657853A (en) * 1984-09-14 1987-04-14 E. I. Du Pont De Nemours And Company Immunoassays utilizing covalent conjugates of polymerized enzyme and antibody
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
PT1530482E (pt) 2002-07-18 2014-01-15 Helix Biopharma Corp Utilização de urease para inibição de crescimento de células cancerigenas
US7723099B2 (en) * 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
WO2013185215A1 (en) * 2012-06-12 2013-12-19 Amorfix Life Sciences Ltd. Antibodies and conjugates that target misfolded prion protein

Also Published As

Publication number Publication date
AU2014252666A1 (en) 2015-11-12
JP2016524459A (ja) 2016-08-18
AU2014252666B2 (en) 2017-02-02
EP2984170A4 (en) 2016-11-30
CA2908475A1 (en) 2014-10-16
US20160138002A1 (en) 2016-05-19
WO2014165985A1 (en) 2014-10-16
CA2908475C (en) 2020-09-08
CN105247047A (zh) 2016-01-13
CN109248311A (zh) 2019-01-22
US10316311B2 (en) 2019-06-11
EP2984170A1 (en) 2016-02-17

Similar Documents

Publication Publication Date Title
HK1214828A1 (zh) 抗體/藥物綴合物及使用方法
ZA201408236B (en) Anti-ly6e antibodies and immunoconjugates and methods of use
LT2806892T (lt) Kombinuota terapija, panaudojant antikūnus ir endoglikozidazes
GB201302447D0 (en) Therapeutic and diagnostic target
EP2970494A4 (en) HER3 SPECIFIC MONOCLONAL ANTIBODIES FOR USE IN DIAGNOSIS AND THERAPEUTICS
HK1216903A1 (zh) 抗體-尿素酶偶聯物在診斷和治療中的應用
PT2984108T (pt) Anticorpos anti-s100a7 para o tratamento e diagnóstico de cancro
HUE050547T2 (hu) Oligoszaccharid konjugátumok és alkalmazási eljárások
GB201303308D0 (en) Therapeutic and diagnostic target
GB201309498D0 (en) Novel diagnosis and therapy
GB201302884D0 (en) Novel methods for diagnosis and therapy
GB201301685D0 (en) Diagnosis and treatment of cancer
GB201303532D0 (en) Therapeutic and diagnostic target
GB201303535D0 (en) Therapeutic and diagnostic target
GB201303529D0 (en) Therapeutic and diagnostic target
GB201303486D0 (en) Therapeutic and diagnostic target
GB201303429D0 (en) Therapeutic and diagnostic target
GB201303408D0 (en) Therapeutic and diagnostic target
GB201303415D0 (en) Therapeutic and diagnostic target
GB201303395D0 (en) Therapeutic and diagnostic target
GB201303404D0 (en) Therapeutic and diagnostic target
GB201303389D0 (en) Therapeutic and diagnostic target
GB201303373D0 (en) Therapeutic and diagnostic target
GB201303298D0 (en) Therapeutic and diagnostic target
GB201303319D0 (en) Therapeutic and diagnostic target